Monoclonal antibodies approved for the treatment of brain tumors
| Medication | Tumor type | Mechanism of action |
|---|---|---|
| Bevacizumab | Glial tumors which include GBM (primary and recurrent) [13] | Binds to and inhibits VEGF leading to a reduction in microvascular growth which limits blood supply to tumors [14] |
| Naxitamab-gqgk | Neuroblastoma and GD-2 positive cancers [15] | Humanized monoclonal antibody [15, 16] |
| Dinutuximab [16] | Neuroblastoma | Anti-GD-2 monoclonal antibody [16] |
VEGF: vascular endothelial growth factor
BLW: Conceptualization, Supervision, Writing—review & editing. MM: Conceptualization, Project administration, Visualization. MS, AS and MM: Writing—original draft, Writing—review & editing
The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Uniformed Services University of the Health Sciences, the Department of Defense, or the U.S. Government.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2023.